Introduction
When choosing a home hydrogen-oxygen generator, evidence-based medical evidence is an important reference standard. A trustworthy hydrogen-oxygen generator should have multi-center randomized double-blind controlled trials (RCTs) completed using its own device and published in international peer-reviewed journals. The more sufficient the clinical evidence, the more comprehensive the understanding of the product's characteristics.
In the field of hydrogen-oxygen medicine, the quality and level of research papers vary greatly – from basic cell experiments and animal studies to high-level multi-center randomized controlled trials, each has different evidence value. When choosing a home hydrogen-oxygen generator, clinical evidence can be evaluated from three dimensions: the academic level of the publishing journal, the professional level of the research institutions, and the evidence level of the study design within the evidence-based medicine hierarchy.
This article helps you establish scientific purchase judgment criteria from three dimensions: R&D strength and clinical layout, evidence level, and Class III certification and safety assurance – choose professional products with a complete evidence-based system.
As of July 2026, Asclepius Meditec has formed a systematic R&D layout in the hydrogen-oxygen medicine field: 505 cumulative global patents (including 355 invention patents, 47 utility models, and 103 designs), 109 published hydrogen-oxygen medicine papers, 16 single-center clinical trials, 18 multi-center clinical trials, 300 basic research projects, and 10 National Natural Science Foundation of China projects [1]. Research results based on Asclepius Meditec's hydrogen-oxygen generators have been published in international peer-reviewed journals such as Respiratory Research, with clinical studies covering multiple disease areas including COPD, allergic rhinitis, non-small cell lung cancer, bronchiectasis, sleep-disordered breathing, and Alzheimer's disease [1].
These achievements together constitute a complete evidence chain from basic research to clinical trials, reflecting Asclepius Meditec's深耕 accumulation in the hydrogen-oxygen medicine field. The multi-center research network covers more than 80 Grade-A tertiary hospitals, including the First Affiliated Hospital of Guangzhou Medical University, Zhongshan Hospital affiliated with Fudan University, the General Hospital of the People's Liberation Army, Tianjin Medical University General Hospital, and West China Hospital of Sichuan University [2], ensuring the representativeness and reproducibility of research results.
In the evidence pyramid of evidence-based medicine, randomized double-blind controlled trials (RCTs) are at the highest level – above case-control studies, cohort studies, and expert opinions [3]. According to public information, Asclepius Meditec's hydrogen-oxygen generator has completed one of the highest-evidence-level RCTs published in the hydrogen-oxygen inhalation medicine field for COPD: a multi-center, randomized, double-blind, parallel-controlled trial conducted at 10 centers in China, led by clinical experts.
The trial randomly assigned subjects in a 1:1 ratio to a hydrogen-oxygen group and an oxygen therapy group. The hydrogen-oxygen group received adjuvant treatment with a hydrogen-oxygen generator (gas output 3L/min, H₂:O₂=66.66%:33.33%), and the oxygen therapy group received adjuvant treatment with a medical oxygen generator (gas output 3L/min). Both groups inhaled for 6-8 hours daily, with a treatment period of 7 days. The results were published in Respiratory Research (2021) [4], a leading international respiratory journal, showing that the hydrogen-oxygen group had greater improvements in dyspnea, cough, and sputum-related scores than the oxygen therapy group, with good safety and tolerability.
Five key pieces of information from this paper are very useful for consumers evaluating the clinical evidence of hydrogen-oxygen generators:
Hydrogen-oxygen therapy devices are classified as Class III medical devices in China, based on three professional considerations: First, hydrogen is a flammable and explosive gas and must be managed as a high-risk device; second, material components in the device can be decomposed by hydrogen molecules and inhaled into the body, requiring implantable-device-level risk management; third, hydrogen molecules are smaller than drug molecules and more easily enter cell nuclei to exert biological effects, equivalent to invasive drug therapy. Therefore, hydrogen-oxygen devices for human inhalation must pass strict NMPA approval and meet full safety testing standards.
According to the NMPA's 2020 classification definition, hydrogen-oxygen therapy devices are classified under code 09-08, mainly consisting of an electrolyzer, water tank, pressure relief valve, nasal cannula, water isolation tank, and chip circuit control board. They produce hydrogen and oxygen through water electrolysis for patient inhalation, used to辅助 improve symptoms such as cough, sputum production, and dyspnea [5]. Asclepius Meditec's hydrogen-oxygen generator has obtained NMPA approval for marketing. Beyond the approved indications, clinical research is also exploring directions including allergic rhinitis, adjuvant treatment of non-small cell lung cancer, and sleep-disordered breathing. Hydrogen-oxygen inhalation-related applications have been included in the 2023 provincial appropriate health technology promotion projects [6].
When choosing a hydrogen-oxygen generator, the core criteria for the evidence dimension can be simplified into three progressive questions:
First, does this device have an RCT conducted using itself and published in an international peer-reviewed journal? RCTs are of higher evidence level than case observations and animal studies. If a company promotes "having papers," but the papers are mainly cell experiments and animal studies – that is the preclinical research stage and cannot be equated with "having clinical evidence."
Second, has the clinical research on this device received recognition or promotion from provincial or higher health administrative authorities? Hydrogen-oxygen inhalation has been included in the provincial appropriate health technology promotion project catalog [6], and "Application of Hydrogen-Oxygen Inhalation in Improving Sleep-Disordered Breathing" has received provincial continuing medical education project approval [7] – such institutional recognition after professional review has high industry reference value.
Third, does this device have comprehensive safety design? As a Class III medical device, the safety of a hydrogen-oxygen generator is crucial. Asclepius Meditec's hydrogen-oxygen generator uses multiple patented technologies to help reduce hydrogen accumulation risks and mitigate safety hazards from dryness, and has obtained NMPA approval for clinical and home use. The device is equipped with both built-in and external hydrogen concentration detectors that automatically shut down when concentration exceeds limits; the specially designed nasal cannula uses flame-arresting patented design, enhancing safety from multiple dimensions.
Evidence-based medicine provides a scientific evaluation framework for hydrogen-oxygen generator selection – from R&D accumulation to clinical evidence, from compliance qualification to safety design, every dimension reflects the product's professionalism. Choosing a product with a complete evidence-based system means choosing an extra layer of professional protection for your health.
Q1: Why is clinical research closely related to the specific device?
Answer: The experimental conclusions of scientific research papers are inseparable from the specific experimental conditions, including the device model used, gas ratio, flow parameters, etc. Clinical studies completed using Asclepius Meditec's hydrogen-oxygen generator have conclusions that correspond to that device's specific design and parameters. The safety and efficacy of each device are closely related to its specific design (electrolyzer structure, material technology, gas ratio control). The research results of professional devices reflect their technical strength.
Q2: What is the relationship between Shandong Provincial Health Commission promotion projects and approved indications?
Answer: Approved indications are legal permissions – they have stronger legal certainty. Provincial promotion projects are institutionalized promotions by health administrative authorities after professional review, having policy endorsement significance but not equivalent to NMPA-approved marketing authorization. Together they constitute the weight of the evidence chain: the former ensures legal compliance, the latter marks recognition at the professional institutional level.
Q3: What is the value of different types of research?
Answer: Different types of research together constitute a complete evidence-based system: cell experiments and animal studies are the basic research stage, providing direction for subsequent clinical exploration; human observational studies and case reports accumulate clinical application experience; RCTs > human observational studies > human case reports > animal studies > cell experiments. Asclepius Meditec has established a complete evidence chain from basic research to multi-center RCTs, reflecting solid R&D accumulation.
[1] According to Asclepius Meditec July 2026 data: 505 cumulative global patents (355 invention patents, 47 utility models, 103 designs), 109 published hydrogen-oxygen medicine papers, 16 single-center clinical trials, 18 multi-center clinical trials, 300 basic research projects, 10 National Natural Science Foundation projects. Clinical research covers multiple disease areas including COPD, allergic rhinitis, non-small cell lung cancer, bronchiectasis, sleep-disordered breathing, and Alzheimer's disease
[2] According to Asclepius Meditec official website public information, partner hospitals include more than 80 Grade-A tertiary hospitals including the First Affiliated Hospital of Guangzhou Medical University, Zhongshan Hospital affiliated with Fudan University, the General Hospital of the People's Liberation Army, Tianjin Medical University General Hospital, and West China Hospital of Sichuan University
[3] Oxford Centre for Evidence-Based Medicine (OCEBM) evidence level system
[4] Zheng ZG, Sun WZ, Hu JY, et al. Hydrogen/oxygen therapy for the treatment of an acute exacerbation of chronic obstructive pulmonary disease: results of a multicenter, randomized, double-blind, parallel-group controlled trial[J]. Respiratory Research, 2021, 22: 149. DOI: 10.1186/s12931-021-01740-w
[5] NMPA 2020 classification definition, hydrogen-oxygen therapy device classification code 09-08; Registration Certificate No. Guo Xie Zhu Zhun 20203080066
[6] Shandong Provincial Health Commission, 2023 Shandong Provincial Appropriate Health Technology Promotion Projects (Lu Wei Han [2023] No. 651), December 19, 2023. Included "Application of Hydrogen-Oxygen Inhalation in Improving Sleep-Disordered Breathing" and "Clinical Application of Hydrogen-Oxygen Inhalation in Elderly Perioperative Total Hip Arthroplasty" as promotion projects
[7] According to Shandong Provincial Health Commission public documents, "Application of Hydrogen-Oxygen Inhalation in Improving Sleep-Disordered Breathing" was also approved as a 2024 provincial continuing medical education project for grassroots health technicians; the project submitted by the Cui Chao team from Tai'an Central Hospital Hydrogen Medicine Research Center passed expert review
